2QK.F SCHOLAR ROCK HLDG DL-001

Healthcare Biotechnology Frankfurt Exchange
41.59 EUR
Close of Nov 11, 2026
25.40 53.00
Market cap
EUR 5.07B
P/E
-
P/B
34.99x
ROE
-169.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2QK.F undervalued?

Graham number

The Graham number of SCHOLAR ROCK HLDG DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SCHOLAR ROCK HLDG DL-001 fundamental analysis

No fundamental analysis for SCHOLAR ROCK HLDG DL-001 yet.

SCHOLAR ROCK HLDG DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SCHOLAR ROCK HLDG DL-001

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal…

Full company profile